2663 related articles for article (PubMed ID: 7675773)
21. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical status of p53, mdm2 and Ki-67 in malignant fibrous histiocytoma.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1998; 49(1):15-21. PubMed ID: 9640970
[TBL] [Abstract][Full Text] [Related]
23. Differential diagnosis of atypical epithelium of biopsied gastric mucosa using immunostaining of Ki-67, p53, hMLH1 and MDM2 expression.
Ito E; Saito K; Takizawa T; Koike M
J Exp Clin Cancer Res; 2002 Dec; 21(4):527-37. PubMed ID: 12636099
[TBL] [Abstract][Full Text] [Related]
24. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
Böni R; Doguoglu A; Burg G; Müller B; Dummer R
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):416-8. PubMed ID: 8784279
[TBL] [Abstract][Full Text] [Related]
25. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma.
Barnhill RL; Castresana JS; Rubio MP; Martin MT; Idoate M; Vazquez JJ; Thor AD
Mod Pathol; 1994 Jun; 7(5):533-5. PubMed ID: 7937717
[TBL] [Abstract][Full Text] [Related]
26. Expression of mdm-2 and p53 protein in transitional cell carcinoma.
Barbareschi M; Girlando S; Fellin G; Graffer U; Luciani L; Dalla Palma P
Urol Res; 1995; 22(6):349-52. PubMed ID: 7537927
[TBL] [Abstract][Full Text] [Related]
27. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study.
Leuschner I; Langhans I; Schmitz R; Harms D; Mattke A; Treuner J;
Pediatr Dev Pathol; 2003; 6(2):128-36. PubMed ID: 12574910
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical detection of p53 protein, c-erbB-2 protein, epidermal growth factor receptor protein and proliferating cell nuclear antigen in gastric carcinoma.
Jang WI; Yang WI; Lee CI; Kim HS; Song KS; Cho MY; Park JK; Shim YH
J Korean Med Sci; 1993 Aug; 8(4):293-304. PubMed ID: 7911025
[TBL] [Abstract][Full Text] [Related]
30. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions.
Maelandsmo GM; Holm R; Fodstad O; Kerbel RS; Flørenes VA
Am J Pathol; 1996 Dec; 149(6):1813-22. PubMed ID: 8952518
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of p53 is a late event in the development of malignant melanoma.
Lassam NJ; From L; Kahn HJ
Cancer Res; 1993 May; 53(10 Suppl):2235-8. PubMed ID: 8485708
[TBL] [Abstract][Full Text] [Related]
32. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes.
Guerriere-Kovach PM; Hunt EL; Patterson JW; Glembocki DJ; English JC; Wick MR
Am J Clin Pathol; 2004 Jul; 122(1):70-7. PubMed ID: 15272532
[TBL] [Abstract][Full Text] [Related]
33. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Droller MJ
J Urol; 2001 May; 165(5):1811-2. PubMed ID: 11345951
[No Abstract] [Full Text] [Related]
34. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
35. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
36. Image cytometric analysis of p53 and mdm-2 expression in primary and recurrent mucoepidermoid carcinoma of parotid gland: immunohistochemical study.
Abd-Elhamid ES; Elmalahy MH
Diagn Pathol; 2010 Nov; 5():72. PubMed ID: 21092204
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi.
Saenz-Santamaría MC; Reed JA; McNutt NS; Shea CR
J Cutan Pathol; 1994 Oct; 21(5):393-7. PubMed ID: 7868749
[TBL] [Abstract][Full Text] [Related]
38. Expression and significance of P53 protein and MDM-2 protein in human gliomas.
Wang AL; Liu ZX; Li G; Zhang LW
Chin Med J (Engl); 2011 Aug; 124(16):2530-3. PubMed ID: 21933600
[TBL] [Abstract][Full Text] [Related]
39. Mutation and expression of TP53 in malignant melanomas.
Weiss J; Heine M; Arden KC; Körner B; Pilch H; Herbst RA; Jung EG
Recent Results Cancer Res; 1995; 139():137-54. PubMed ID: 7597286
[TBL] [Abstract][Full Text] [Related]
40. Cell proliferation markers in predicting metastases in malignant melanoma.
Reddy VB; Gattuso P; Aranha G; Carson HJ
J Cutan Pathol; 1995 Jun; 22(3):248-51. PubMed ID: 7593819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]